Literature DB >> 27429524

Quantification of Transfusion Recipients at Risk of Receiving Hepatitis B Virus-Contaminated Blood Components: A Korean Study.

Kunsei Lee1, Hyeongsu Kim1, Sounghoon Chang1, Mina Hur2, Vitna Kim1, Hyoseon Jeong1, Dong Hee Seo3, SangWon Lee4, Eun Jung Kim5, Eunyoung Shin6, Young Tack Kim7.   

Abstract

Although there are lots of studies about the risk for the hepatitis B virus infection such as the residual risk for donated blood, there is no research on the risk of HBV infection, from the viewpoint of recipients in Korea. Using the data about HBsAg status of donated blood in 2008 and 2009, the distribution of blood components from the claim data of health insurance in 2009, the distribution of HBsAg and HBsAb of recipients, and some assumptions, we quantified the number of recipients in Korea that might be expected to receive HBV-contaminated blood components, as a proxy index for HBV infection by transfusion in 2009. Of the 376,211 recipients, the number who might be expected to receive blood components with HBV in 2009 was 23.2 (95 % CI 13.6, 36.8) in the basic model, 43.2 (95 % CI 25.4, 68.7) in extended model I, 55.2 (95 % CI 32.5, 87.7) in extended model II and 101.6 (95 % CI 59.8, 161.4) in extended model III. The number of HBV-positive samples per 100,000 transfused units was 0.6 in the basic model (95 % CI 0.3, 0.9), 1.1 in extended model I (95 % CI 0.6, 1.8), 1.4 in extended model II (95 % CI 0.8, 2.2), and 2.6 in extended model III (95 % CI 1.5, 4.1). This study showed that a few recipients might receive HBV-contaminated blood component by transfusion. These results could be used as a scientific evidence for health policy on HBV transfusion infection.

Entities:  

Keywords:  Blood component; Hepatitis B; Residual risk; Transfusion

Year:  2015        PMID: 27429524      PMCID: PMC4930750          DOI: 10.1007/s12288-015-0564-8

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  21 in total

1.  Individual nucleic amplification technology does not prevent all hepatitis B virus transmission by blood transfusion.

Authors:  Shoichi Inaba; Akira Ito; Yoshihisa Miyata; Hiroyuki Ishii; Shoko Kajimoto; Masatsugu Tanaka; Atsuo Maruta; Satoru Saito; Hisao Yugi; Minabu Hino; Kenji Tadokoro
Journal:  Transfusion       Date:  2006-11       Impact factor: 3.157

2.  [An experience of the use of Anti-HBc and Anti-HBs for blood donor screening tests at a tertiary hospital blood center in Korea].

Authors:  Young Ae Lim; Seokho Yoon
Journal:  Korean J Lab Med       Date:  2009-02

3.  Chronic hepatitis B: update 2009.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

Review 4.  Hepatitis B virus infection and transfusion medicine: science and the occult.

Authors:  F Blaine Hollinger
Journal:  Transfusion       Date:  2008-05       Impact factor: 3.157

5.  Prevalence of antibodies to hepatitis B core antigen and occult hepatitis B virus infections in Korean blood donors.

Authors:  Dong Hee Seo; Dong Hee Whang; Eun Young Song; Hyun Soo Kim; Quehn Park
Journal:  Transfusion       Date:  2011-02-18       Impact factor: 3.157

Review 6.  Transfusion-transmitted hepatitis B virus infection.

Authors:  Daniel Candotti; Jean-Pierre Allain
Journal:  J Hepatol       Date:  2009-06-10       Impact factor: 25.083

7.  Anti-HBs positive occult hepatitis B virus carrier blood infectious in two transfusion recipients.

Authors:  Snezna Levicnik-Stezinar; Urska Rahne-Potokar; Daniel Candotti; Nico Lelie; Jean-Pierre Allain
Journal:  J Hepatol       Date:  2008-03-28       Impact factor: 25.083

8.  The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study.

Authors:  G B Schreiber; M P Busch; S H Kleinman; J J Korelitz
Journal:  N Engl J Med       Date:  1996-06-27       Impact factor: 91.245

9.  Residual risk of transfusion-transmitted infection with human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in Korea from 2000 through 2010.

Authors:  Moon Jung Kim; Quehn Park; Hyuk Ki Min; Hyun Ok Kim
Journal:  BMC Infect Dis       Date:  2012-07-20       Impact factor: 3.090

10.  Pre- and post-transfusion testing for hepatitis B virus surface antigen and antibody in blood recipients: a single-institution experience in an area of high endemicity.

Authors:  Hyeongsu Kim; Mina Hur; Hee-Won Moon; Chul Min Park; Jin-Hee Cho; Kyoung Sik Park; Kunsei Lee; Sounghoon Chang
Journal:  Ann Lab Med       Date:  2011-12-20       Impact factor: 3.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.